379 related articles for article (PubMed ID: 33050934)
1. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
Menzies-Gow A; Colice G; Griffiths JM; Almqvist G; Ponnarambil S; Kaur P; Ruberto G; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
Respir Res; 2020 Oct; 21(1):266. PubMed ID: 33050934
[TBL] [Abstract][Full Text] [Related]
2. DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
Menzies-Gow A; Ponnarambil S; Downie J; Bowen K; Hellqvist Å; Colice G
Respir Res; 2020 Oct; 21(1):279. PubMed ID: 33087119
[TBL] [Abstract][Full Text] [Related]
3. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
Wechsler ME; Colice G; Griffiths JM; Almqvist G; Skärby T; Piechowiak T; Kaur P; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
Respir Res; 2020 Oct; 21(1):264. PubMed ID: 33050928
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.
Corren J; Menzies-Gow A; Chupp G; Israel E; Korn S; Cook B; Ambrose CS; Hellqvist Å; Roseti SL; Molfino NA; Llanos JP; Martin N; Bowen K; Griffiths JM; Parnes JR; Colice G
Am J Respir Crit Care Med; 2023 Jul; 208(1):13-24. PubMed ID: 37015033
[No Abstract] [Full Text] [Related]
5. CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.
Emson C; Diver S; Chachi L; Megally A; Small C; Downie J; Parnes JR; Bowen K; Colice G; Brightling CE
Respir Res; 2020 Oct; 21(1):265. PubMed ID: 33050900
[TBL] [Abstract][Full Text] [Related]
6. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
Menzies-Gow A; Wechsler ME; Brightling CE
Respir Res; 2020 Oct; 21(1):268. PubMed ID: 33059715
[TBL] [Abstract][Full Text] [Related]
7. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
Menzies-Gow A; Corren J; Bourdin A; Chupp G; Israel E; Wechsler ME; Brightling CE; Griffiths JM; Hellqvist Å; Bowen K; Kaur P; Almqvist G; Ponnarambil S; Colice G
N Engl J Med; 2021 May; 384(19):1800-1809. PubMed ID: 33979488
[TBL] [Abstract][Full Text] [Related]
8. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
Diver S; Khalfaoui L; Emson C; Wenzel SE; Menzies-Gow A; Wechsler ME; Johnston J; Molfino N; Parnes JR; Megally A; Colice G; Brightling CE;
Lancet Respir Med; 2021 Nov; 9(11):1299-1312. PubMed ID: 34256031
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Menzies-Gow A; Wechsler ME; Brightling CE; Korn S; Corren J; Israel E; Chupp G; Bednarczyk A; Ponnarambil S; Caveney S; Almqvist G; Gołąbek M; Simonsson L; Lawson K; Bowen K; Colice G;
Lancet Respir Med; 2023 May; 11(5):425-438. PubMed ID: 36702146
[TBL] [Abstract][Full Text] [Related]
10. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR).
Pavord ID; Hoyte FCL; Lindsley AW; Ambrose CS; Spahn JD; Roseti SL; Cook B; Griffiths JM; Hellqvist Å; Martin N; Llanos JP; Martin N; Colice G; Corren J
Ann Allergy Asthma Immunol; 2023 Nov; 131(5):587-597.e3. PubMed ID: 37619779
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR study.
Ishizuka T; Menzies-Gow A; Okada H; Fukushima Y; Hayashi N; Colice G; Ponnarambil S; Hunter G; Odajima H; Ebisawa M
Allergol Int; 2023 Jan; 72(1):82-88. PubMed ID: 35977863
[TBL] [Abstract][Full Text] [Related]
12. Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study.
Menzies-Gow A; Ambrose CS; Colice G; Hunter G; Cook B; Molfino NA; Llanos JP; Israel E
Adv Ther; 2023 Nov; 40(11):4957-4971. PubMed ID: 37723356
[TBL] [Abstract][Full Text] [Related]
13. Tezepelumab in Adults with Uncontrolled Asthma.
Corren J; Parnes JR; Wang L; Mo M; Roseti SL; Griffiths JM; van der Merwe R
N Engl J Med; 2017 Sep; 377(10):936-946. PubMed ID: 28877011
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study.
Corren J; Ambrose CS; Griffiths JM; Hellqvist Å; Lindsley AW; Llanos JP; Colice G; Menzies-Gow A
Clin Exp Allergy; 2023 Apr; 53(4):417-428. PubMed ID: 36507576
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.
Wechsler ME; Menzies-Gow A; Brightling CE; Kuna P; Korn S; Welte T; Griffiths JM; Sałapa K; Hellqvist Å; Almqvist G; Lal H; Kaur P; Skärby T; Colice G;
Lancet Respir Med; 2022 Jul; 10(7):650-660. PubMed ID: 35364018
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study.
Carr TF; Moore WC; Kraft M; Brusselle G; Castro M; Chupp GL; Wechsler ME; Hunter G; Lindsley AW; Llanos JP; Burke LK; Chandarana S; Ambrose CS
Adv Ther; 2024 May; ():. PubMed ID: 38802635
[TBL] [Abstract][Full Text] [Related]
17. Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study.
Corren J; Karpefors M; Hellqvist Å; Parnes JR; Colice G
J Asthma Allergy; 2021; 14():1-11. PubMed ID: 33469316
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
[TBL] [Abstract][Full Text] [Related]
19. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.
Busse WW; Maspero JF; Rabe KF; Papi A; Wenzel SE; Ford LB; Pavord ID; Zhang B; Staudinger H; Pirozzi G; Amin N; Akinlade B; Eckert L; Chao J; Graham NMH; Teper A
Adv Ther; 2018 May; 35(5):737-748. PubMed ID: 29725983
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy.
Corren J; Ambrose CS; Sałapa K; Roseti SL; Griffiths JM; Parnes JR; Colice G
J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4334-4342.e6. PubMed ID: 34358701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
